Abstract:HER2 is a driver gene identified in non-small-cell lung cancer (NSCLC). The prevalence, clinicopathology and genetic variability of HER2 mutation non-small cell lung cancer patients are unclear. The aim of this study is to investigate mutational subtypes and prognosis of NSCLC harboring HER2 mutations. A total of 781 patients with NSCLC were recruited between July 2012 and December 2014. The status of HER2 mutation and other genes were detected by reverse transcription polymerase chain reaction (RT-PCR) or next generation sequencing. HER2 gene mutation rate was 1.92%(15/781) in NSCLC, including S310F (2 patients), A775_G776insYVM (2 patients), S280F (2 patients), P780_Y781insGSP (1 patient), C630Y (1 patient), L755P (1 patient), T327S (1 patient), K907R (1 patient), R70W (1 patient), E117D (1 patient), L970V (1 patient), and C965S (1 patient). Mutation rate of female was much higher than male (3.76% vs 1.23%, P=0.022), and current-smoker was much higher than no-smoker (3.17% vs 0.74%, P=0.027), and median overall survival (OS) for these patients was 42.6 months. Among them, 12 patients with co-occurring mutations had a median OS of 42.6 months, and median OS of the 3 patients without complex mutations was 40.3 months. No statistically significant difference was found between the two groups (P=0.43). Briefly, patients with (n=8) or without (n=7) co-occurring EGFR mutations had a median OS of 50.6 months and 42.6 months respectively (P=0.19); patients with (n=9) or without (n=6) co-occurring TP53 mutations had a median OS of 40.4 months and 46.7 months respectively (P=0.39); patients with (n=2) or without (n=13) co-occurring SMARCA4 mutations had a median OS of 50.6 months and 42.6 months respectively (P=0.33); patients with (n=2) or without (n=13) co-occurring MTOR mutations had a median OS of 44.3 months and 42.6 months respectively (P=0.71); patients with (n=2) or without (n=13) co-occurring SMARCA4 mutations had a median OS of 50.6 months and 42.6 months respectively (P=0.33); patients with (n=2) or without (n=13) co-occurring APC mutations had a median OS of 39.0 months and 42.6 months respectively (P=0.92). There are some significant differences of molecular features in HER2 gene mutations with non-smoking women in NSCLC, along with the state of HER2 gene mutations little influence on prognosis. Afatinib treatment may displayed moderate efficacy in patients with HER2 mutations.

EP1.03-03 Association Between Molecular Spectrum of EZH2 Variants and Prognosis in Patients with Non-Small-Cell Lung Cancer in Chinese Patients

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

Morphologic and Molecular Correlates of EZH2 As a Predictor of Platinum Resistance in High-Grade Ovarian Serous Carcinoma.

P2.03-08 Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer

EP1.03-19 the Frequency and Prognosis of MDM2 Mutations in East Asian Non-Small-Cell Lung Cancer Patients

P3.03-08 Analysis of ESR1 Mutation Spectrum from Non-Small-Cell Lung Cancer in Chinese Patients

Expression and clinical significance of ezrin in non--small-cell lung cancer.

Identification of Prognostic miRNAs Targeting EZH2 in Hepatocellular Carcinoma Using The Cancer Genome Atlas Database

EP1.03-07 Prevalence and Clinicopathological Characteristics of EIF1AX Mutations in Chinese Patients with Non-Small Cell Lung Cancer

The relationship of EZH2 and HOXA5 with non-small cell lung carcinoma patient survival rate

P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

P1.03-28 Association Between Molecular Characteristics of CTNNB1 Mutations and Prognosis in Patients with Nsclc in Chinese Patients

P1.03-35 Analysis of TET2 Gene Aberrations in East Asian Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis

EP1.03-35 Prevalence, Clinicopathologic Characteristics, and Molecular Associations of IGF1R Mutations in East Asian Patients with NSCLC

EP1.03-28 Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

P1.03-32 Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients

EP1.03-24 Clinicopathologic Characteristics and Survival Outcome in Chinese Patients with Non-Small Cell Lung Cancer and HGF Mutations

P1.03-03 Molecular Characteristics of Chinese Patients with TSC2-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

The Prevalence and Prognostic Significance of JAK2 Mutation Subtypes in Non-Small Cell Lung Cancer from Chinese Populations.